Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis
NCT05642208Phase 4Completed
- Sponsor
- CHU de Nantes
- Start
- Mar 2023
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by CHU de Nantes. Started Mar 2023; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05642208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642208.